About Cocrystal Pharma, Inc. - Common Stock (COCP)
Cocrystal Pharma Inc. is a biotechnology company focused on the development of innovative antiviral therapies to treat various viral infections. The company utilizes its proprietary drug discovery platform to create novel compounds aimed at inhibiting viral replication and targeting specific viral targets. Cocrystal Pharma is particularly engaged in research related to hepatitis and influenza, striving to address unmet medical needs in the field of infectious diseases. Through its scientific advancements and strategic partnerships, the company aims to deliver effective treatments that can significantly improve patient outcomes. Read More
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.
LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses, according to the company's website (see here: https://www.cocrystalpharma.com/).
The Dow Jones closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
